Market research
MLND Millendo Therapeutics, Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.48
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US87978U1088
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.48
About
About Millendo Therapeutics, Inc
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MLND discussion.
5 years, 4 months ago
Millendo Therapeutics, Inc is currently in a long term downtrend where the price is trading 43.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Millendo Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.3% to $36K since the same quarter in the previous year.
Finally, its free cash flow grew by 314.4% to $25M since the same quarter in the previous year.
Based on the above factors, Millendo Therapeutics, Inc gets an overall score of 3/5.